Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks. #pharma #biospace https://t.co/Vw8g8wppNx

The deal is done. What happens next for Pfizer and Metsera—and Novo? #merger #biospace https://t.co/Yw3LBUAZy7

A new generation of companies is eyeing the existing, sizeable hair loss market, hoping that better formulations and new scientific targets will finally produce treatments that are safer and more effective, as well as commercially successful. #drugdevelopment #weightloss

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ongoing bidding war between Novo Nordisk and Pfizer over obesity biotech Metsera. #GLP1 #drugpricing #biospace https://t.co/Tnu7HRG3Vd

Following restricted vaccine approvals and changes to CDC immunization schedules, Merck, Pfizer, GSK and Sanofi are all suffering revenue hits to their vaccine programs. #vaccines #pharma #biospace https://t.co/BiTPC070pn

The Phase III results impressed Guggenheim Partners analysts both in terms of efficacy and safety. If approved, atacicept would become the first APRIL/BAFF inhibitor for IgAN to make it to the market. #pharma #biospace https://t.co/ibTQuUDAQK

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex-z. #genetherapy #CRISPR #biospace https://t.co/OWw2oW9IoI

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of progression to active disease. #pharma #biospace https://t.co/WZYlMtRVYm

The nausea and other gastrointestinal side effects of weight loss drugs like Novo Nordisk’s Wegovy or Eli Lilly’s Zepbound will limit how much these drugs can help patients and stunt the overall obesity market unless we approach the problem head on. #opinion #GLP1 #obesity

Ready, Set, Rumble! The wait is over – Sonic Rumble is live worldwide on iOS, Android, and Steam 🌍 Join Sonic in the ultimate arcade royale where up to 32 players battle for glory!

The FDA awards a second round of Commissioner’s National Priority vouchers to six larger biopharma companies. And this time, with the exception of Eli Lilly’s orforglipron, the vouchers are for drugs that are already on the market. #regulatory #FDA #biopharma #biospace

The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting campaign is helping to stem the downward trend. #earnings #pharma #biospace https://t.co/s8huBP470o

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially. #drugpricing #GLP1 #weightloss #biospace https://t.co/EIzRtXoiNP

The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets. #obesity #weightloss #biospace

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based on “the medical aspect” of weight loss, including driving down visceral fat. #earnings #obesity #weightloss #biospace https://t.co/2HRoyqEBdg

The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on Sunday. Deputy Director Mike Davis is in the running, along with Mary Thanh Hai, currently head of the Office of New Drugs. #FDA #CDER #pharma #biospace

The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk’s higher bid. #pharma #biospace https://t.co/meSveEekYq

Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera: The antitrust watchdog has spotted issues with the structure of Novo’s bid, while its New York-based rival has put more money on the table. #obesity #FTC #biotech #biospace

While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be. #radiopharmaceuticals #biospace https://t.co/w3HHINoRTH

In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb. #podcast technology #clinicaltrials #biospace https://t.co/CRfQfH6wrV

The Basel area is home to over 800 life sciences companies, including @Novartis and @Roche, according to nonprofit @BaselArea. The nonprofit’s CEO and a @BeOneMedicines executive discuss the location’s evolution, advantages and future. #basel #biopharma #biospace

NEAR Intents just doubled its daily volume ATH with $200M in the last 24 hours 🔥 Unstoppable liquidity is NEAR